15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
11:00 , Nov 15, 2018 |  BC Extra  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
17:40 , Mar 17, 2017 |  BC Week In Review  |  Company News

Ataxion, Luc Therapeutics deal

Ataxion will merge with Luc; the newco will retain Luc's name and focus on precision medicine for neurological and psychiatric diseases. Its pipeline includes programs to treat ataxia, schizophrenia and depression, which is being developed...
02:24 , Feb 5, 2015 |  BC Extra  |  Company News

The Medicines Co. acquires Annovation

The Medicines Co. (NASDAQ:MDCO) exercised its option to acquire Annovation Biopharma Inc. (Cambridge, Mass.) for $28.4 million in cash up front. Annovation shareholders are eligible for up to $26.3 million in clinical and regulatory milestones,...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Atlas' next chapter

After separating from the tech group, Atlas Venture 's healthcare team plans to stick to the early stage investing strategy the firm says has provided returns in the top quartile of life science VCs. For...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Ataxion, Biogen Idec, Saniona deal

Strategic investor Biogen Idec is providing Ataxion undisclosed non-dilutive R&D and other funding and will invest in the company's planned $17 million series A round. Virtual company Ataxion is developing compounds that target an undisclosed...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Financial News

Ataxion completes venture financing

Ataxion Inc. , Cambridge, Mass.   Business: Neurology   Date completed: 3/17/14   Type: Venture financing   Raised: Not disclosed   Investors: Atlas Ventures; Biogen Idec Inc.   Note: The company raised an undisclosed amount...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Ataxion board of directors update

Ataxion Inc. , Cambridge, Mass.   Business: Neurology   Appointed: Steven Holtzman, EVP of corporate development at Biogen Idec Inc. ; and Kevin Koch, SVP of R&D at Biogen Idec  ...
07:00 , Mar 24, 2014 |  BioCentury  |  Finance

Quick turn

Quick turn In less than a year, Atlas has set up a potential exit for Ataxion Inc. via a $17 million tranched series A round that will fund the company through completion of a Phase...